Journal of Shandong University (Health Sciences) ›› 2019, Vol. 57 ›› Issue (10): 107-111.doi: 10.6040/j.issn.1671-7554.0.2019.691

Previous Articles    

Effects of serum levels of sEGFR, CEA and Cyfra21-1 on the prognosis of non-small cell lung cancer patients

XU Shuyuan, JI Quanjiang, GUO Li   

  1. Department of Clinical Laboratory, Affiliated Hospital of Shandong Academy of Medical Sciences, Shandong First Medical University, Jinan 250031, Shandong, China
  • Published:2022-09-27

PDF (PC)

61

Abstract: Objective To investigate the correlation between the expression levels of serum soluble epidermal growth factor receptor(sEGFR), carcinoembryonic antigen(CEA), cytokeratin 19 fragment(Cyfra21-1), and overall survival of patients with non-small cell lung cancer(NSCLC). Methods Altogether 127 NSCLC cases were involved, including 42 cases of squamous carcinoma and 85 cases of adenocarcinoma. The TNM stage was II+III in 45 cases and IV in 82 cases. The sEGFR expression was detected with ELISA, and CEA and cyfra21-1 levels were detected with electrochemical luminescence. The relationship between the levels of sEGFR, CEA, Cyfra21-1 and the clinicopathological characteristics and prognosis of NSCLC patients were analyzed. Results The expressions of sEGFR and CEA in NSCLC patients were correlated with the clinical stage (P<0.05). Patients with adenocarcinoma showed significantly higher CEA than patients with squamous carcinoma (P<0.05), while serum Cyfra21-1 had no statistically significant characteristics (P>0.05). The median survival of patients with reduced serum sEGFR, increased CEA, and increased Cyfra21-1 was 9.0(4.0-21.25)months, 8.5(4.0, 16.0)months and 8.0(4.0, 13.25)months, respectively, which were statistically significant compared with patients with normal expressions (P<0.05). Conclusion The decrease of sEGFR, increase of CEA and Cyfra21-1 in patients with NSCLC is significantly correlated with the overall survival, and the prognosis can be assessed by detecting the serum levels of sEGFR, CEA and Cyfra21-1. 山 东 大 学 学 报 (医 学 版)57卷10期 -徐淑媛,等.血清sEGFR、CEA及Cyfra21-1水平对非小细胞肺癌患者预后的影响 \=-

Key words: Non-small cell lung cancer, Soluble epidermal growth factor receptor, Carcinoembryonic antigen, Cytokeratin 19 fragment, Prognosis

CLC Number: 

  • R734.2
[1] 仰杰, 尤青海, 孟凡亮, 等. 非小细胞肺癌miR-211表达与功能初步研究[J]. 中华肿瘤防治杂志, 2018, 25(11): 773-777. YANG Jie, YOU Qinghai, MENG Fanliang, et al. Expression and function of miR-211 in non-small cell lung cancer [J]. Chinese Journal of Cancer Prevention and Treatment, 2018, 25(11): 773-777.
[2] Ye S, Chen X, Yao Y, et al. Thioredoxin reductase as a novel and efficient plasma biomarker for the detection of non-small cell lung cancer: a Large-scale, Multicenter study [J]. Sci Rep, 2019, 9(1): 2652.
[3] 吕丽婷, 刘益飞, 刘军, 等. EHD2在非小细胞肺癌中的表达及其临床意义[J]. 实用医学杂志, 2017, 33(22): 3769-3772. LV Liting, LIU Yifei, LIU Jun, et al. EHD2 expression and clinical significance in non-small cell lung cancer [J]. The Journal of Practical Medicine, 2017, 33(22): 3769-3772.
[4] 周婉婉, 梁冰, 王效静, 等. 非小细胞肺癌患者外周血hTERT mRNA水平检测的临床意义[J]. 东南大学学报(医学版), 2017, 36(2): 217-221. ZHOU Wanwan, LIANG Bing, WANG Xiaojing, et al. The level of hTERT mRNA in peripheral blood of non-small cell lung cancer detected by real-time PCR [J]. Journal Southeast University(Medical Science Edition), 2017, 36(2): 217-221.
[5] Zhang L, Liu D, Li L, et al. The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonicantigen and neuron-specific enolase in lung cancer patients [J]. BMC Cancer, 2017, 17(1): 96. doi: 10.1186/s12885-017-3070-6.
[6] Detterbeck FC, Boffa DJ, Kim AW, et al. The eighth edition lung cancer stage classification [J]. Chest, 2017, 151(1): 193-203.
[7] Xu CH, Yang Y, Wang YC, et al. Prognostic significance of serum chemerin levels in patients with non-small cell lung cancer [J]. Oncotarget, 2017, 8(14): 22483-22489.
[8] Shigehiro Y, Hidehito H, Kuniko SS, et al. Impact of KRAS mutation on response and outcome of patients with stage III non-squamous non-small cell lung cancer [J]. Cancer Sci, 2015,106(10): 1402-1407.
[9] Wang N, Guo H, Dong Z, et al. Establishment and validation of a 7-microRNA prognostic signature for non-small cell lung cancer [J]. Cancer Manage Res, 2018, 12(10): 3463-3471.
[10] Wang J, Jiang W, Zhang T, et al. Increased CYFRA 21-1, CEA and NSE are prognostic of poor outcome for locally advanced squamous cell carcinoma in lung: a nomogram and recursive partitioning risk stratificantion analysis[J]. TranslOncol, 2018, 11(4): 999-1006.
[11] Singh P, Srivastava AN, Sharma R, et al. Circulating MicroRNA-21 expression as a novel serum biomarker for oral sub-mucous fibrosis and oral squamous cell carcinoma[J]. Asian Pac JCancer Prev, 2018, 19(4): 1053-1058.
[12] He Y, Cui Y, Chang D, et al. Postoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I pulmonary adenocarcinoma[J]. Oncotarget, 2017, 8(42): 73115-73122.
[13] Jin J, Si J, Liu Y, et al. Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy[J]. Respir Res, 2018, 19(1): 197. doi: 10.1186/s12931-018-0885-x.
[14] 冯晓云, 葛琴, 陆志斌. 非小细胞肺癌患者血清miR-133b的表达水平及其临床意义探讨[J].东南大学学报(医学版), 2015, 34(6): 934-937. FENG Xiaoyun, GE Qin, LU Zhibin. Serum miR-133b levels and its relation with clinical pathological characteristics in non-small cell lung cancer patients[J]. Journal of Southeast University(Medical Science Edition), 2015, 34(6): 934-937.
[15] Zhu W, Zhou K, Zha Y, et al. Diagnostic value of serum miR-182, miR-183, miR-210, and miR-126 levels in patients with early-stage non-small cell lung cancer[J]. PLoS ONE, 2016, 11(4): e0153046. doi: 10.1371/journal.pone.0153046.
[16] Liu AM, Zhu Y, Huang ZW, et al. Long noncoding RNA FAM201A involves in radioresistance of non-small-cell lung cancer by enhancing EGFR expression via miR-370[J]. Eur Rev Med Pharmacol Sci, 2019, 23(13): 5802-5814.
[17] Filippo L, Massimiliano P, Cristian R, et al. Preliminary evidence on the diagnostic and molecular role of circulating soluble EGFR in non-small cell lung cancer[J]. Mol Sci, 2015, 16(8): 19612-19630.
[18] Hui R, Yang H, Tao X, et al. Effect of gefitinib on serum EGFR and CYFRA21-1 in patients with advanced non-small cell lung cancer[J]. Oncol Lett, 2019, 18(4): 4167-4175.
[19] Romero-Ventosa EY, Blanco-Prieto S, González-Pi(~overn)eiro AL, et al. Pretreatment levels of the serum biomarkers CEA, CYFRA 21-1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients [J]. Springer Plus, 2015, 9(4): 171. doi: 10.1186/s40064-015-0891-0. eCollection 2015.
[20] Dai L, Qu Y, Li J, et al. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer [J]. Oncotarget, 2017, 8(22): 36664-36673.
[21] Dal Bello MG, Filiberti RA, Alama A, et al. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer(NSCLC)patients [J]. J Transl Med, 2019, 17(1): 74. doi: 10.1186/s12967-019-1828-0.
[22] Mauro C, Passerini R, Spaggiari L, et al. New and old biomarkers in the differential diagnosis of lung cancer: pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1 [J]. Int J Biol Markers, 2019, 34(2):163-167.
[23] Wang XB, Li J, Han Y. Prognostic significance of preoperative serum carcinoembryonic antigen in non-small cell lung cancer: a metaanalysis[J]. Tumor Biol, 2014, 35(10): 10105-10110.
[24] Baek AR, Seo HJ, Lee JH, et al. Prognostic value of baseline carcinoembryonic antigen and cytokeratin 19 fragment levels in advanced non-small cell lung cancer [J]. Cancer Biomarker, 2018, 22(1): 55-62.
[25] Parka SY, Leea JG, Kimb J, et al. Preoperative serum CYFRA 21-1 level as a prognostic factor in surgically treated adenocarcinoma of lung [J]. Lung Cancer, 2013, 79(2): 156-160.
[1] ZHENG Su, CHEN Shuhua, LI Hua, DENG Jie, CHEN Chunhong, WANG Xiaohui, FENG Weixing, HAN Xiaodi, ZHANG Yujia, LI Na, LI Mo, FANG Fang. Correlation between EEG variations and BASED evaluation of the efficacy of ACTH treatment in 54 cases of infantile spasms [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 91-96.
[2] WANG Lihui, GAO Min, KONG Beihua. Angiosarcoma of the uterus: a report of 2 cases and literature review [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 108-112.
[3] HE Shiqing, LI Wanwan, DONG Shuqing, MOU Jingyi, LIU Yuying, WEI Siyu, LIU Zhao, ZHANG Jiaxin. Construction of a prognostic risk model of pyroptosis-related genes in breast cancer based on database [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 34-43.
[4] QIN Jing, YANG Fei, CHEN Qian, XIA Handai, LIU Yanguo, WANG Xiuwen. A network meta-analysis of first-line treatment options for patients with advanced driver-gene wild-type and PD-L1 negative non-squamous non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 74-82.
[5] ZHANG Yufeng, XU Min, XING Xiuli, PANG Shuguang, HU Keqing. Epidemiological characteristics of 689 patients with non-ST-segment elevation myocardial infarction [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 118-122.
[6] LI Linlin, WANG Kai. Prediction of hepatocellular carcinoma prognostic genes based on bioinformatics [J]. Journal of Shandong University (Health Sciences), 2022, 60(5): 50-58.
[7] CHEN Zhaobo, FANG Min, XUE Haoran, LIU Chunyan. Deubiquitinase USP35 promotes the cells migration and invasion of non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 30-37.
[8] CHU Yan, LIU Duanrui, ZHU Wenshuai, FAN Rong, MA Xiaoli, WANG Yunshan, JIA Yanfei. Expressions of DNA methyltransferases in gastric cancer and their clinical significance [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 1-9.
[9] CHEN Liyu, XIAO Juan, LYU Xianzhong, DUAN Baomin, HONG Fanzhen. Risk factors influencing prognosis of lower extremity deep vein thrombosis in pregnant and parturient women [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 38-42.
[10] TIAN Yaotian, WANG Bao, LI Yeqin, WANG Teng, TIAN Liwen, HAN Bo, WANG Cuiyan. Machine learning models based on interpretive CMR parameters can predict the prognosis of pediatric myocarditis [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 43-49.
[11] LI Wanwan, ZHOU Wenkai, DONG Shuqing, HE Shiqing, LIU Zhao, ZHANG Jiaxin, LIU Bin. Construct of a risk assessment model of breast cancer immune-related lncRNAs based on the database information [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 74-84.
[12] MI Qi, SHI Shuang, LI Juan, LI Peilong, DU Lutao, WANG Chuanxin. Construction of circRNA-mediated ceRNA network and prognostic assessment model for bladder cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 94-102.
[13] LI Xiangqing, YIN Xin, ZHAO Xuelian, ZHAO Peiqing. Expression and clinical significance of circulating CD56bright subset of NK cells in patients with Parkinsons disease [J]. Journal of Shandong University (Health Sciences), 2021, 59(2): 34-40.
[14] ZENG Rui, HU Xinting, YUN Xiaoya, TIAN Zheng, LI Qing, LIU Jie, ZHANG Ya, WANG Xin. Fluorescence in situ hybridization in the diagnosis of 197 cases of chronic lymphocytic leukemia [J]. Journal of Shandong University (Health Sciences), 2021, 59(11): 35-40.
[15] LI Yinglin, SONG Daoqing, XU Zhonghua. Identification of FKBP11 expression in clear cell renal cell carcinoma using bioinformatics analysis [J]. Journal of Shandong University (Health Sciences), 2020, 1(9): 45-51.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd